Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:ATCCode |
L01EX13
|
| gptkbp:CASNumber |
915769-50-5
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:hasMolecularFormula |
C24H27N5O2
|
| gptkbp:hasSMILES |
CCOC1=CC(=C(C=C1N2C=NC3=NC=CC(=C3N2)C4=C(C=CC=C4Cl)Cl)N)OCCN5CCOCC5
|
| gptkbp:hasUNII |
6Z5B6HVF6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
dovitinib
|
| gptkbp:investigatedBy |
gptkb:cancer
gptkb:endometrial_cancer multiple myeloma hepatocellular carcinoma renal cell carcinoma |
| gptkbp:IUPACName |
6-(2,6-dichlorophenyl)-2-[(3-ethoxy-4-morpholin-4-ylphenyl)amino]pyrido[2,3-d]pyrimidin-7(8H)-one
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:molecularWeight |
417.51 g/mol
|
| gptkbp:PubChem_CID |
DB11760
CHEMBL354494 11290322 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
CHIR-258
TKI-258 TKI258 |
| gptkbp:target |
gptkb:FGFR
gptkb:PDGFR gptkb:VEGFR |
| gptkbp:bfsParent |
gptkb:FGFR1
|
| gptkbp:bfsLayer |
6
|